Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of integrating artificial intelligence (AI) with genomic data for oncology drug discovery, has announced the addition of Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop, renowned for his leadership in biotechnology and his expertise in developing targeted therapies for solid tumors, including HK327M-mutant gliomas, brings over two decades of experience to Lantern Pharma. His previous role as co-founder and CEO of Oncoceutics Inc., which was acquired in significant transactions by Chimerix Inc. and later by Jazz Pharmaceuticals, underscores his impact in the field.
Panna Sharma, CEO of Lantern Pharma, highlighted the alignment of Dr. Schalop's expertise in neurooncology and strategic transactions with the company's mission. Lantern Pharma's AI-powered drug development platform, particularly its CNS cancer pipeline at subsidiary Starlight Therapeutics, stands to benefit from Dr. Schalop's insights. Dr. Schalop expressed his enthusiasm for contributing to Lantern's precision oncology programs, aiming to bring forth innovative treatments for patients with limited options.
This appointment is a testament to Lantern Pharma's commitment to leveraging AI and machine learning to revolutionize the oncology drug development process. The company's RADR(R) platform, which utilizes over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms, has already demonstrated its potential by advancing drug programs from initial AI insights to clinical trials in just 2-3 years, at a fraction of the traditional cost.
The strategic inclusion of Dr. Schalop in Lantern Pharma's leadership team not only enhances the company's expertise in precision oncology but also signals its ambition to lead in the development of AI-driven cancer therapies. For investors and the oncology community, this move underscores the growing importance of AI in drug discovery and the potential for Lantern Pharma to emerge as a key player in the field.
